The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda
Category: Merck & Co
Up to 20% of prostate cancer cases are classified as castration-resistant
pharmaceuticals.co.nz
Drugs, medicines and medical news